Funding, M&A, exec moves and hiring — matched to your market, with the people to call.See plans →
City Therapeutics secures $99.5 million in Series B funding to enhance its RNAi pipeline, led by prominent investors. The funds will advance its lead asset CITY-FXI and support business development activities.
PRIVATEJun 08, 2026•2 months ago
Amount Raised
$99.5 Million
Round Type
Series B
CambridgeBiotechnologyHealth CareTherapeutics
Description
City Therapeutics has raised $99.5 million in a Series B funding round to further develop RNA interference medicines. The funds will be directed towards advancing CITY-FXI, aimed at preventing blood clots, alongside enhancements to its RNAi engineering platform. City is also working on therapies for Stargardt disease and other undisclosed targets. This financing underscores the company's progress in leading next-gen RNAi-based medicines.
Company Information
Company
City Therapeutics
Location
Cambridge, Massachusetts, United States
About
City Therapeutics is a biopharmaceutical company harnessing next-generation engineering of RNAi trigger molecules to improve and expand the reach of RNAi-based medicines. The company is building a pipeline of innovative RNAi therapeutics to make a significant impact for patients across multiple therapeutic areas. Co-founded by pioneering executives and scientists in RNAi, City Therapeutics is based in Cambridge, MA, and has raised $135 million from leading life sciences investors.
Related People
Suggested for you
1 contact
Verified contactsNo contacts on file at City Therapeutics yet.
Predictive Intelligence
Strategic
ML-powered predictions for City Therapeutics's next move
CambridgeBiotechnologyHealth CareTherapeutics